ウイルスベクター製造市場レポート：動向、予測、競合分析 (2031年まで)

世界のウイルスベクター製造市場の将来は、製薬・バイオ医薬品市場や研究機関市場にチャンスがあり、有望視されています。世界のウイルスベクター製造市場は、2025年から2031年までのCAGRが18.7%で、2031年までに推定36億米ドルに達すると予想されます。この市場の主な促進要因は、ウイルスベクターを用いた治療に対する需要の増加、ウイルスベクター製造への投資の増加、ウイルスベクター製造の技術進歩です。

• Lucintel社の予測によると、用途別では、がん、希少疾患、遺伝性疾患など幅広い疾患の治療に対する細胞・遺伝子治療への需要が高まっていることから、予測期間中、細胞・遺伝子治療が最も高い成長を遂げる見込みです。
• 最終用途産業別では、製薬・バイオ医薬品企業が、がん、希少疾患、感染症を含む広範な疾患に対するウイルスベクターベースの治療法を開発・商業化しているため、製薬・バイオ医薬品が最大のセグメントであり続けると思われます。
• 地域別では、北米の製薬・バイオテクノロジー業界からのウイルスベクターベースの治療薬に対する需要が増加しているため、予測期間中に北米が最も高い成長を遂げると予想されます。

ウイルスベクター製造市場の戦略的成長機会

ウイルスベクター製造市場は、主要な用途におけるいくつかの戦略的機会により、大幅な成長を遂げています。このような成長は、技術的進歩や遺伝子治療に対する需要の増加によって牽引されており、一方で治療用途の地平は広がっています。本論では、成長機会のある5つの主要分野を紹介し、ウイルスベクター製造市場への影響を概略します。

• ワクチン開発：市場では、ウイルスベクター技術によるワクチン開発が急速に拡大しています。感染症や新興病原体に対するワクチンは、ウイルスベクターを用いて開発されています。COVID-19ワクチンにおけるウイルスベクターの使用は、ワクチン開発におけるその可能性を実証しています。製造業者には、ベクター技術を強化し、感染症、がん、その他の健康状態をターゲットとした新しく改良されたワクチンの製造に役立つよう、生産規模を拡大する機会があります。
• 個別化医療：遺伝子ベースの個別化医療は、ウイルスベクター製造に新たな市場ニッチを提供します。遺伝子編集や標的遺伝子導入などの個別化治療は、ウイルスベクターを必要とします。個別化医療が一般的になるにつれ、特定の患者のニーズに対応するカスタマイズされたウイルスベクターに対する需要が高まっています。この動向は、柔軟な生産ソリューションを提供し、革新的なベクターシステムを開発することで利用することができます。
• 新しい市場：ウイルスベクター製造は、アジア太平洋やラテンアメリカのような新興市場に新たな成長の道を開いています。これらの地域ではバイオ医薬品セクターが発展し、ヘルスケアへの投資が増加しているため、ウイルスベクターの需要が高まっています。より高い成長率での拡大を望む企業は、遺伝子治療や細胞治療の需要増加に対応するため、現地パートナーを探し、新興市場の状況を利用し、地域に生産施設を設立し、規制状況を効果的に調整することを余儀なくされています。

業界の拡大は、遺伝子・細胞治療用途、ワクチン開発、個別化医療、新興国市場など、ウイルスベクター製造市場における戦略的成長機会によってもたらされています。生命を改善する医薬品に対する需要の増加に対応しながら、これらの重要な分野に注力することで、市場での存在感を高めることができます。このような機会がウイルスベクター製造の成長を促進し、将来の方向性を形成し続けると思われます。

ウイルスベクター製造市場の促進要因・課題

いくつかの力と課題がウイルスベクター製造市場のダイナミクスを定義しています。主な成長促進要因としては、技術革新、より優れた治療技術に対する需要の増加、財政投資の拡大などが挙げられます。逆に、この業界は高い製造コスト、規制の複雑さ、技術的な複雑さといった欠点にも直面しています。この市場のプレーヤーにとって、これらの要因を理解することは、潜在的な課題を克服するための最適な戦略を決定する上で極めて重要です。

ウイルスベクター製造市場を牽引する要因は以下の通りである：

• 技術進歩：技術進歩は、ウイルスベクター製造市場の成長を促進する大きな力となっています。自動化、シングルユース技術、高度な分析機能などの技術革新により、製造時の効率性、拡張性、品質が向上しています。このような技術改善により、単位時間当たりの生産量を確保しながらコストを削減し、生産者はウイルスベクターの需要増に対応できるようになります。技術がさらに進歩すれば、生産能力を向上させ、新たな治療法の開発活動を促進する機会ももたらされるであろう。
• より高度な医薬品への需要の高まり：遺伝子治療や細胞治療に対する需要の高まりは、市場の成長を促す重要な要因です。臨床試験から商業化に移行する治療法の数が増加しているため、治療遺伝子を送達するためのより優れたウイルスベクターが必要とされています。その結果、メーカー各社は生産能力を拡大し、新技術への投資を促しています。ウイルスベクター製造分野のさらなる拡大と技術革新は、先端治療の成長によって推進されます。
• バイオ医薬品への投資の増加：ウイルスベクター製造市場の成長は、バイオ医薬品産業への投資の増加によって促進されます。官民からの資金援助により、研究開発や新たな製造施設の設立が促進されます。バイオ医薬品のインフラや技術への投資は、生産規模を拡大し能力を強化するために必要です。投資の増加に伴い、ウイルスベクター製造のさらなる改善が期待され、市場の成長につながります。

ウイルスベクター製造市場の課題は以下の通りです：

• 高い製造コスト：ウイルスベクター製造は高い製造コストに直面しており、これが大きな課題となっています。特殊な設備と高品質の原材料を必要とするウイルスベクター製造工程が複雑であるため、追加コストが発生します。さらに、厳格な規制基準を遵守することは、企業にとって経済的負担となります。これらのコスト課題に対処するには、製造プロセスの革新と、市場内での収益性と持続可能性を確保するための費用対効果の高い技術への投資が必要です。
• 規制クリアランスの難しさ：ウイルスベクター製造業界は、規制に関する課題に直面しています。製品の安全性と有効性は、複雑で変化し続ける規制を遵守することで確保されなければなりません。適正製造基準（GMP）ガイドラインを遵守し、規制当局の承認を得るにはコストがかかります。こうした課題を克服するため、メーカーは規制の変更に耐えうる品質管理対策に多額の投資を行う必要があります。コンプライアンスを効率的に管理することは、市場へのアクセスを維持し、ウイルスベクターに基づく治療法の商業化を成功させるために不可欠です。

結論として、市場力学はウイルスベクター製造市場が直面する促進要因・課題によって形成されます。市場の成長は、技術的進歩、先端治療に対する需要の高まり、投資の増加によって推進される一方で、製造コストの高騰や規制上のハードルに関する課題も根強く残っています。技術革新と戦略的投資を通じてこれらの課題を克服することが、市場の継続的な成功と拡大には不可欠です。

目次

第1章 エグゼクティブサマリー

第2章 世界のウイルスベクター製造市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 市場動向と予測分析 (2019年～2031年)

• マクロ経済動向 (2019～2024年) と予測 (2025～2031年)
• 世界のウイルスベクター製造市場の動向 (2019～2024年) と予測 (2025～2031年)
• 世界のウイルスベクター製造市場：種類別
  • アデノウイルス
  • レトロウイルス
  • アデノ随伴ウイルス
  • レンチウイルス
  • プラスミドDNA
  • その他
• 世界のウイルスベクター製造市場：ワークフロー別
  • 上流製造
  • 下流製造
• 世界のウイルスベクター製造市場：用途別
  • 細胞・遺伝子治療
  • ワクチン学
  • 研究、その他の要路
• 世界のウイルスベクター製造市場：最終用途別
  • 製薬・バイオ医薬品
  • 研究機関
  • その他

第4章 地域別の市場動向と予測分析 (2019年～2031年)

• 世界のウイルスベクター製造市場：地域別
• 北米のウイルスベクター製造市場
• 欧州のウイルスベクター製造市場
• アジア太平洋のウイルスベクター製造市場
• その他地域のウイルスベクター製造市場

第5章 競合分析

• 製品ポートフォリオ分析
• 運用統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略分析

• 成長機会分析
  • 世界のウイルスベクター製造市場の成長機会：種類別
  • 世界のウイルスベクター製造市場の成長機会：ワークフロー別
  • 世界のウイルスベクター製造市場の成長機会：用途別
  • 世界のウイルスベクター製造市場の成長機会：最終用途別
  • 世界のウイルスベクター製造市場の成長機会：地域別
• 世界のウイルスベクター製造市場の新たな動向
• 戦略的分析
  • 新製品の開発
  • 世界のウイルスベクター製造市場の生産能力拡大
  • 世界のウイルスベクター製造市場における企業合併・買収 (M&A)、合弁事業
  • 認証とライセンシング

第7章 主要企業のプロファイル

• Merck
• Lonza
• FUJIFILM Diosynth Biotechnologies
• Thermo Fisher Scientific
• Cobra Biologics
• Catalent
• Wuxi Biologics
• Takara Bio
• Waisman Biomanufacturing
• Genezen laboratories

The future of the global viral vector manufacturing market looks promising with opportunities in the pharmaceutical & biopharmaceutical and research institutes markets. The global viral vector manufacturing market is expected to reach an estimated $3.6 billion by 2031 with a CAGR of 18.7% from 2025 to 2031. The major drivers for this market are the increasing demand for viral vector-based therapies, growing investment in viral vector manufacturing, and technological advancements in viral vector manufacturing.

• Lucintel forecasts that, within the application category, cell and gene therapy is expected to witness the highest growth over the forecast period due to the growing demand for cell and gene therapies for the treatment of a wide range of diseases, including cancer, rare diseases, and genetic disorders.
• Within the end use industry category, pharmaceutical and biopharmaceutical will remain the largest segment because these pharmaceutical and biopharmaceutical companies are developing and commercializing viral vector-based therapies for a wide range of diseases, including cancer, rare diseases, and infectious diseases.
• In terms of regions, North America is expected to witness the highest growth over the forecast period due to increasing demand for viral vector-based therapies from the pharmaceutical and biotechnology industries in the region.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Viral Vector Manufacturing Market

The viral vector manufacturing market is undergoing significant changes, driven by emerging trends that are reshuffling the industry. Some of these trends include progress in production technologies, increased demand for gene and cell therapies, collaboration between private firms and institutions of higher learning, growth of disposable technology platforms, and a notable emphasis on regulatory compliance. While improving productivity and scalability in viral vector manufacturing, these trends also help address issues related to cost structures, quality control, and supply chain challenges.

• Manufacturing Technologies Advancements: A key trend in the viral vector manufacturing market is advancements in manufacturing technologies. The production of viral vectors is being revolutionized by novel inventions like automated production systems, single-use bioreactors, and high-throughput screening. More effective and scalable methods are currently being made possible through these developments, which save time and costs related to production. Additionally, downstream processing and purification methods have advanced, leading to better quality and greater quantities of viral vectors. These advancements will significantly impact manufacturing efficiency as they become more popular, thus contributing to the growth of the market.
• Uneven Surge in Gene and Cell Therapies: A significant factor driving the viral vector manufacturing market's growth is the increasing demand for gene and cell therapies. The requirement for high-quality viral vectors has been driven by the transition of more gene and cell therapies from clinical trials to commercialization. This has prompted manufacturers to expand their production capacity and develop new facilities to cater to the increasing market size. Furthermore, recent successful gene therapies have attracted more investor attention to the industry, leading to increased funding for viral vector manufacturing capabilities. This trend is projected to continue, thereby further expanding the market.
• Advocates for More Collaboration and Partnerships: A major trend in the viral vector manufacturing market is the increased collaboration among pharmaceutical companies, academic institutions, and CMOs. These associations help promote innovation and expedite the development of new viral vector generation methods. These partnerships result in more efficient production processes through the pooling of resources and expertise, as well as the development of new therapies. This is also giving rise to various strategic alliances aimed at expanding manufacturing capabilities while improving the availability of viral vectors. In conclusion, it can be said that increasing partnerships will lead to major market progressions.
• Emphasis on Regulatory Compliance: Another significant trend in viral vector manufacturing is a strong emphasis on regulatory compliance. As the sector expands, manufacturers are increasingly focused on strict regulatory norms that guarantee the safety and effectiveness of their products. These include adherence to Good Manufacturing Practices (GMP) as well as compliance with regional and global regulations. Consequently, a focus on regulatory compliance has led manufacturers to adopt quality control systems, advanced analytics, and efficient documentation procedures. As regulatory demands evolve, keeping pace with them will be vital for drug firms to thrive in the competitive viral vector industry.

The landscape of viral vector manufacturing is changing due to technological advancements, a rise in demand for gene therapies, increased collaborative activities, greater use of single-use technologies, and the importance of regulatory compliance. Innovation propelled by these trends will enhance production efficiency and expand market reach. As such, it is anticipated that this sector will continue to grow while creating new avenues for viral vector manufacturing companies. To maintain momentum and ensure long-term success in the market, continued focus in these areas is crucial.

Recent Developments in the Viral Vector Manufacturing Market

Recent developments in the viral vector manufacturing market have led to significant improvements driven by the increased demand for gene and cell therapies. These developments include advancements in production technology, expansion of manufacturing capacity, and improvements in regulatory compliance procedures. Important changes are occurring with the growth of the market, which intends to concentrate on improving efficiency, scalability, and quality control processes. Such developments enhance viral vector production, yielding better outcomes for therapeutic applications needed by the industry.

• Expansion of Manufacturing Facilities: Recent expansions in manufacturing facilities are crucial for meeting the growing demand for viral vectors. Major biopharmaceutical companies are investing in new production sites and updating existing ones. These efforts aim to expand capacity, enhance scalability, and improve production efficiency. New facilities often incorporate advanced technologies such as automated systems and single-use technologies to streamline processes and ensure high-quality outputs. This development is vital to supporting the increased volume of gene and cell therapies reaching the marketplace and addressing supply chain challenges.
• Embracing Advanced Concepts: Viral vector manufacturing is evolving due to the adoption of advanced technologies. Examples include, but are not limited to, automation, AI, and high-throughput screening. The manufacturing process is simplified using automated systems, thus reducing human error and increasing output. Process optimization and quality control can be enhanced through AI and machine learning. These technologies also enable higher yields and faster production cycles that meet the rising demand for viral vectors in support of advanced therapeutic solutions.
• Novel Viral Vectors Development: The emergence of new viral vectors is expanding gene therapy options. This is achieved by creating brand-new viral vector systems with superior safety profiles, improved transduction efficiencies, and enhanced tissue targeting. These improvements address traditional vector limitations, including low tissue specificity or immune responses. In general, novel vectors facilitate better-targeting approaches for a variety of genetic disorders and cancers. This development thus expands the spectrum of therapeutic applications, leading to further progress in the gene therapy sector.
• Increased Emphasis on Quality and Compliance: The viral vector manufacturing market is being shaped by a heightened emphasis on quality and regulatory compliance. Manufacturers are investing in robust quality control mechanisms that enforce strict regulatory standards to ensure product safety and efficacy. This includes the adoption of Good Manufacturing Practice (GMP) guidelines and advanced analytical methods for process monitoring. Enhanced quality assurance practices help prevent contamination, ensuring that products remain consistently high-quality, which is vital for regulatory approvals and maintaining confidence in viral vector-based therapeutics.

The viral vector manufacturing market is currently experiencing significant developments such as facility expansions, new vector development, quality improvements, and the rise of partnerships, all of which are having a substantial impact on the industry. These changes will enhance manufacturing capacity, efficiency, and quality, which are critical factors for meeting the growing needs for gene and cell therapies. With further development expected as the market continues to evolve, these advances will be instrumental in driving growth and innovation, thereby positioning viral vector production for continued prosperity.

Strategic Growth Opportunities for Viral Vector Manufacturing Market

The viral vector manufacturing market is witnessing substantial growth due to several strategic opportunities across key applications. This progression has been driven by increased technological advancements and demand for gene therapies, while the therapeutic application horizon has prospered. This discussion presents five major areas where there are growth opportunities, outlining their impacts on the viral vector manufacturing market.

• Vaccine Development: * Within the marketplace, vaccine development through viral vector technology has emerged as a rapidly expanding field. Vaccines for infectious diseases and emerging pathogens are being developed using viral vectors. The use of viral vectors in COVID-19 vaccines has demonstrated their potential in vaccine development. Manufacturers have an opportunity to enhance vector technologies and scale up production to help produce new and improved vaccines targeting infectious diseases, cancer, and other health conditions.
• Personalized Medicine: Genetic-based personalized medicine offers a new market niche for viral vector manufacturing. Personalized therapies, such as gene editing or targeted gene delivery, require viral vectors. As individualized medicine becomes more common, there is a growing demand for customized viral vectors that address particular patient needs. This trend can be exploited by offering flexible production solutions and developing innovative vector systems.
• New Markets: Viral vector manufacturing is opening up new avenues of growth in emerging markets like Asia-Pacific and Latin America. The demand for viral vectors is rising as these regions develop their biopharmaceutical sectors and invest more in healthcare. This desire to expand at a higher rate has compelled businesses to seek local partners, take advantage of the emerging market landscape, establish regional production facilities, and navigate regulatory frameworks effectively to meet the increasing demand for gene and cell therapies.

Industry expansion has been driven by strategic growth opportunities in the viral vector manufacturing market, such as gene and cell therapy applications, vaccine development, personalized medicine, and emerging markets. Market presence can be improved by focusing on these important areas while responding to the increased demand for life-improving medications. These opportunities will continue to drive growth in viral vector manufacturing, shaping its future course.

Viral Vector Manufacturing Market Driver and Challenges

Several forces and challenges define the dynamics of the viral vector manufacturing market. Some of the primary growth drivers include innovation, increasing demand for better treatment techniques, and greater financial investments. Conversely, the industry faces drawbacks such as high production costs, regulatory complications, and technical intricacies. For players in this market, understanding these factors is crucial for determining the best strategies to overcome potential challenges.

The factors driving the viral vector manufacturing market include:

• Technological Advancements: Technological advancements have been a major force driving growth in the viral vector manufacturing market. Innovations such as automation, single-use technologies, and advanced analytical capabilities have improved efficiency, scalability, and quality during production. These technological improvements reduce costs while ensuring greater output per unit of time, enabling producers to meet the rising demand for viral vectors. As technology advances further, it will also offer opportunities for enhancing production capacity and facilitating new therapeutic development activities.
• Growing Demand for More Advanced Drugs: The increasing demand for gene and cell therapies is a key factor driving market growth. The rising number of therapies transitioning from clinical trials to commercialization requires better viral vectors to deliver therapeutic genes. Consequently, this prompts manufacturers to expand their production capacities and invest in new technologies. Further expansion and innovation in the viral vector manufacturing sector will be driven by the growth of advanced therapies.
• Increasing Investment in Biopharmaceuticals: The growth of the viral vector manufacturing market is fueled by increased investment in the biopharmaceutical industry. Funding from public and private sectors facilitates research and development as well as the establishment of new manufacturing facilities. Investments in biopharmaceutical infrastructure and technology are necessary to scale up production and enhance capabilities. With rising levels of investment, further improvements in viral vector manufacturing are expected, leading to market growth.

Challenges in the viral vector manufacturing market include:

• High Cost of Production: Viral vector manufacturing faces high production costs, which is a major challenge. Additional costs arise from the complexities of the viral vector production process, which requires specialized equipment and high-quality raw materials. Furthermore, compliance with strict regulatory standards adds a financial burden on companies. Addressing these cost challenges necessitates innovations in manufacturing processes and investments in cost-effective technologies to ensure profitability and sustainability within the market.
• Difficulties in Regulatory Clearance: The viral vector manufacturing industry faces challenges related to regulation. The safety and efficacy of products must be ensured through adherence to complex and ever-changing regulations. Costs are incurred when complying with Good Manufacturing Practice (GMP) guidelines and obtaining regulatory approvals. To overcome these challenges, manufacturers should invest heavily in quality control measures that can withstand regulatory changes. Efficient management of compliance is critical for maintaining access to markets and successfully commercializing therapies based on viral vectors.

In conclusion, market dynamics are shaped by the drivers and challenges facing the viral vector manufacturing market. Market growth is propelled by technological advancements, rising demand for advanced therapies, and increased investments, while challenges persist related to high production costs and regulatory hurdles. Overcoming these challenges through innovation and strategic investments will be essential for the continued success and expansion of the market.

List of Viral Vector Manufacturing Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies viral vector manufacturing companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the viral vector manufacturing companies profiled in this report include-

• Merck
• Lonza
• Fujifilm Diosynth Biotechnologies
• Thermo Fisher Scientific
• Cobra Biologics
• Catalent
• Wuxi Biologics
• Takara Bio
• Waisman Biomanufacturing
• Genezen Laboratories

Viral Vector Manufacturing by Segment

The study includes a forecast for the global viral vector manufacturing market by type, workflow, application, end use, and region.

Viral Vector Manufacturing Market by Type [Analysis by Value from 2019 to 2031]:

• Adenovirus
• Retrovirus
• Adeno-Associated Virus
• Lentivirus
• Plasmid DNA
• Others

Viral Vector Manufacturing Market by Workflow [Analysis by Value from 2019 to 2031]:

• Upstream Manufacturing
• Downstream Manufacturing

Viral Vector Manufacturing Market by Application [Analysis by Value from 2019 to 2031]:

• Cell & Gene Therapy
• Vaccinology
• Research & Other Applications

Viral Vector Manufacturing Market by End Use [Analysis by Value from 2019 to 2031]:

• Pharmaceutical & Biopharmaceutical
• Research Institutes
• Others

Viral Vector Manufacturing Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Viral Vector Manufacturing Market

Viral vector manufacturing is a global market that is growing rapidly due to the increased demand for gene therapies, vaccines, and cell-based treatments. In these processes, viral vectors are used as agents to introduce genetic materials into the cells where they should be placed. In key economies, including the United States, China, Germany, India, and Japan, there have been considerable developments in manufacturing capabilities, regulatory approvals, and technological innovations, among others.

• United States: The growth of viral vector manufacturing in the country is attributable to the increasing usage of gene therapies and vaccines. Major biopharmaceutical companies and contract development and manufacturing organizations (CDMOs) are expanding their production facilities in response to the growing demand. New plants are being constructed, and existing ones are being retrofitted with new technologies to enhance capacity and ensure compliance with GMP standards. These actions bolster America's ability to produce scalable, high-quality viral vectors, establishing it as a global leader and a role model in manufacturing prowess.
• China: In China, the viral vector manufacturing sector is rapidly changing due to strong governmental efforts to enhance biotechnology and gene therapy sectors. The Chinese authorities have made significant investments in biopharmaceutical infrastructure, particularly in viral vector manufacturing facilities. Furthermore, provincial enterprises are adopting high-end production technologies for increased productivity and quality improvement. This collaboration between academia and industry has spurred innovation in viral vectors. Consequently, these trends position China as one of the main global players, with increasing capacity to meet both local and foreign demand for viral vectors.
• Germany: In terms of viral vector manufacturing, Germany leads in innovation while maintaining high standards of quality control and advanced manufacturing processes. German companies are investing in cutting-edge technologies such as automated production systems and single-use bioreactors, which have improved the efficiency and scalability of viral vector production. Additionally, its stringent regulatory framework ensures that manufacturing processes meet the highest quality standards, solidifying Germany's position as a major player in Europe and enhancing its global competitiveness in the biopharmaceutical sector.
• India: India is becoming a formidable force in the viral vector manufacturing market, especially in contract manufacturing. Its skilled labor force and lower production costs make it an attractive destination for outsourcing viral vector production. Indian companies are increasing their manufacturing capacity by investing in new plants and adopting cutting-edge technologies to meet the growing global demand for viral vectors. Moreover, India's regulatory environment is being aligned with international standards, further enhancing its appeal as a leading center for viral vector manufacturing. Thus, India is now positioned as a major supplier on the global market stage.
• Japan: Japan's viral vector manufacturing market is characterized by a blend of emerging technologies and substantial research and development focus. AI and automation are leading ventures for innovation in this field, being undertaken by Japanese companies to enhance accuracy and efficiency in viral vector manufacturing. Furthermore, Japan has a mature regulatory framework that facilitates the rapid development and commercialization of novel therapies. These aspects position Japan as a major player in the viral vector market, leading its competitors in technology advancement and ensuring its competitiveness in the global market.

Features of the Global Viral Vector Manufacturing Market

Market Size Estimates: Viral vector manufacturing market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Viral vector manufacturing market size by various segments, such as by type, workflow, application, end use, and region in terms of value ($B).

Regional Analysis: Viral vector manufacturing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, workflows, applications, end uses, and regions for the viral vector manufacturing market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the viral vector manufacturing market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the viral vector manufacturing market by type (adenovirus, retrovirus, adeno-associated virus, lentivirus, plasmid DNA, and others), workflow (upstream manufacturing and downstream manufacturing), application (cell & gene therapy, vaccinology, and research & other applications), end use (pharmaceutical & biopharmaceutical, research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Viral Vector Manufacturing Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Viral Vector Manufacturing Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Viral Vector Manufacturing Market by Type
  • 3.3.1: Adenovirus
  • 3.3.2: Retrovirus
  • 3.3.3: Adeno-Associated Virus
  • 3.3.4: Lentivirus
  • 3.3.5: Plasmid DNA
  • 3.3.6: Others
• 3.4: Global Viral Vector Manufacturing Market by Workflow
  • 3.4.1: Upstream Manufacturing
  • 3.4.2: Downstream Manufacturing
• 3.5: Global Viral Vector Manufacturing Market by Application
  • 3.5.1: Cell & Gene Therapy
  • 3.5.2: Vaccinology
  • 3.5.3: Research & Other Applications
• 3.6: Global Viral Vector Manufacturing Market by End Use
  • 3.6.1: Pharmaceutical & Biopharmaceutical
  • 3.6.2: Research Institutes
  • 3.6.3: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Viral Vector Manufacturing Market by Region
• 4.2: North American Viral Vector Manufacturing Market
  • 4.2.1: North American Viral Vector Manufacturing Market by Application: Cell & Gene Therapy, Vaccinology, and Research & Other Applications
  • 4.2.2: North American Viral Vector Manufacturing Market by End Use: Pharmaceutical & Biopharmaceutical, Research Institutes, and Others
• 4.3: European Viral Vector Manufacturing Market
  • 4.3.1: European Viral Vector Manufacturing Market by Application: Cell & Gene Therapy, Vaccinology, and Research & Other Applications
  • 4.3.2: European Viral Vector Manufacturing Market by End Use: Pharmaceutical & Biopharmaceutical, Research Institutes, and Others
• 4.4: APAC Viral Vector Manufacturing Market
  • 4.4.1: APAC Viral Vector Manufacturing Market by Application: Cell & Gene Therapy, Vaccinology, and Research & Other Applications
  • 4.4.2: APAC Viral Vector Manufacturing Market by End Use: Pharmaceutical & Biopharmaceutical, Research Institutes, and Others
• 4.5: ROW Viral Vector Manufacturing Market
  • 4.5.1: ROW Viral Vector Manufacturing Market by Application: Cell & Gene Therapy, Vaccinology, and Research & Other Applications
  • 4.5.2: ROW Viral Vector Manufacturing Market by End Use: Pharmaceutical & Biopharmaceutical, Research Institutes, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Viral Vector Manufacturing Market by Type
  • 6.1.2: Growth Opportunities for the Global Viral Vector Manufacturing Market by Workflow
  • 6.1.3: Growth Opportunities for the Global Viral Vector Manufacturing Market by Application
  • 6.1.4: Growth Opportunities for the Global Viral Vector Manufacturing Market by End Use
  • 6.1.5: Growth Opportunities for the Global Viral Vector Manufacturing Market by Region
• 6.2: Emerging Trends in the Global Viral Vector Manufacturing Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Viral Vector Manufacturing Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Viral Vector Manufacturing Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Merck
• 7.2: Lonza
• 7.3: FUJIFILM Diosynth Biotechnologies
• 7.4: Thermo Fisher Scientific
• 7.5: Cobra Biologics
• 7.6: Catalent
• 7.7: Wuxi Biologics
• 7.8: Takara Bio
• 7.9: Waisman Biomanufacturing
• 7.10: Genezen laboratories